Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Impact Of Cold And Warm Ischemia Time On Outcomes For Kidneys Donated After Cardiac Death
C. Brennan¹, P. R. Sandoval², S. A. Husain², D. Tsapepas¹, S. Mohan², L. E. Ratner²
¹New York Presbyterian, New York, NY, ²Columbia University Medical Center, New York, NY
*Purpose: Donors after cardiac death (DCD) organs are frequently being discarded. Prolonged warm (WIT) cold (CIT) ischemia times are often important considerations in the discard…
2019 American Transplant Congress
Apoptosis during Cold Ischemia and Rewarming Involves a Caspase Independent Pathway
S. Jain¹, R. Plenter², T. Nydam², A. Jani¹
¹Renal Division, University of Colorado, Aurora, CO, ²Transplant Microsurgery Program, University of Colorado, Aurora, CO
*Purpose: We have previously shown that hibernating ground squirrels (GS) tolerate core body temperatures of 4°C for several days with a heart rate that is…
2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…
2019 American Transplant Congress
Changes in the Fate of KDPI < 35% Kidneys before and after Implementation of the New Kidney Allocation System
K. Eng, E. Grodstein, L. Castellanos Reyes, L. Teperman, C. Sethna, P. Singer
Northwell Health, Manhasset, NY
*Purpose: Though the chances of long term graft survival are highest with low KDPI kidneys, there is concern that after implementation of the new kidney…
2019 American Transplant Congress
A Safe Anti-A2 Titer for a Succesful A2 Incompatible Kidney Transplantation
G. Nair, M. Ajaimy, J. Graham, L. Liriano-Ward, A. Campbell, C. Pynadath, Y. Azzi, O. Andacoglu, S. Greenstein, M. Kinkhabwala, J. Rocca, E. Akalin
Montefiore Medical Center, Bronx, NY
*Purpose: The new kidney allocation system implemented in December 2014 allowed for use of A2/A2B donors to B recipients. However there is no mandate by…
2019 American Transplant Congress
Risk Factors for 1-5 Year Major Infection Events (MIE) after Kidney Transplant (KTx) Including First-Year Immunosuppression (IS) Data: An Analysis of the Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity (CISTEM) Study
V. Dharnidharka¹, D. Axelrod², Z. Zhang³, M. Schnitzler³, K. Lentine³, B. Kasiske⁴
¹Washington Univ, St. Louis, MO, ²Univ of Iowa, Iowa City, IA, ³Saint Louis Univ, St. Louis, MO, ⁴SRTR, Minneapolis, MN
*Purpose: From our CISTEM study of linked national registries, we reported that older recipient age, female sex, diabetic kidney failure, non-standard-criteria organs, and mTORi-based IS…
2019 American Transplant Congress
The End of Non-Directed Living Kidney Donation: The National Kidney Registry’s Family Voucher Program
M. Cooper¹, D. Leeser², S. Flechner³, J. Verbesey¹, M. Ronin⁴, G. Hil⁴, A. Waterman⁵, J. Veale⁵
¹Georgetown Transplant Institute, Washington, DC, ²East Carolina University, Greenville, NC, ³Cleveland Clinic, Cleveland, OH, ⁴National Kidney Registry, New York, NY, ⁵UCLA, Los Angeles, CA
*Purpose: The continued growth of the National Kidney Registry’s (NKR) Voucher program has extended Kidney Paired Donation (KPD) to include chronological incompatibility which is facilitating…
2019 American Transplant Congress
Can Cardiac Risk Predictor Models Be Trusted in Kidney Transplant Recipients?
K. L. Hoffman¹, R. R. Alloway¹, A. Shields², E. Woodle², A. Govil¹
¹Nephrology & Transplant Medicine, University of Cincinnati, Cincinnati, OH, ²Transplant Surgery, University of Cincinnati, Cincinnati, OH
*Purpose: Kidney transplant recipients (KTR) bear a higher risk of developing cardiovascular disease due to comorbid conditions. Non-invasive cardiovascular risk stratification tools have not been…
2019 American Transplant Congress
Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-Infected End-Stage Renal Disease Patients: Pre vs. Post-Transplant
B. Shelton¹, G. Berdahl¹, D. Sawinski², B. Linas³, P. Reese², M. Mustian¹, R. Reed¹, P. MacLennan¹, J. Locke¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³Boston University School of Medicine, Boston, MA
*Purpose: End-stage renal disease (ESRD) patients co-infected with HCV and HIV have access to effective treatment options for HCV infection. However, they also have access…
2019 American Transplant Congress
CNI-Free Therapy with Iscalimab (anti-CD40 mAb) Preserves Allograft Histology Compared to Standard of Care after Kidney Transplantation
E. Farkash¹, A. Naik¹, H. Tedesco-Silva², B. Nashan³, O. Witzke⁴, M. van den Hoogen⁵, S. Berger⁶, D. M. Cibrik⁷, S. Mulgaonkar⁸, D. B. Leeser⁹, R. Alloway¹⁰, A. Patel¹¹, J. Pratchke¹², C. Sommerer¹³, A. Wiseman¹⁴, A. Van Zuilen¹⁵, U. Laessing¹⁶, J. Rush¹⁶, B. Haraldsson¹⁶
¹Univ of Michigan, Ann Arbor, MI, ²Hospital do Rim, São Paulo, Brazil, ³Univ. Hamburg, Hamburg, Germany, ⁴Univ Essen, Essen, Germany, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶UMC Groningen, Gröningen, Netherlands, ⁷Univ of Kansas, Kansas City, KS, ⁸Saint Barnabas MC, Livingston, NJ, ⁹East Carolina Univ, Greenville, NC, ¹⁰Univ of Cincinnati, Cincinnati, OH, ¹¹Henry Ford Hosp, Detroit, MI, ¹²Charité Univ, Berlin, Germany, ¹³Univ Heidelberg, Heidelberg, Germany, ¹⁴Univ of Colorado SM, Denver, CO, ¹⁵Univ MC, Utrecht, Netherlands, ¹⁶Novartis, Basel, Switzerland
*Purpose: To assess if calcineurin (CNI)-free therapy with iscalimab preserves the quality of transplanted kidney grafts.*Methods: Iscalimab (CFZ533) is a new, fully human, Fc-silenced, non-depleting,…